Molecule to cure. Fast.
Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast.
Because humanity needs solutions, fast.
Watch our video
Welcome
Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients.
Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast. Because humanity needs solutions, fast.
Services
At Quotient Sciences, we have streamlined the drug development process by providing pre-formulation screening, formulation development, first-in-human trials, and clinical & commercial manufacturing services all at one CDMO, allowing us to support drug programs from candidate selection through commercial supply.
Latest updates
-
NewsQuotient Sciences Expands Formulation Development Capabilities at Nottingham, UKAn expansion of our early-phase formulation development capabilities for oral dosage forms at our Nottingham, UK, facility builds upon our existing formulation capabilities.
-
Apr 25Tradeshow & ConferenceInterphex 2023 | New York, NYSchedule a 1:1 meeting with our drug development experts during Interphex 2023 in New York between 25th - 27th April.
-
Info SheetQuotient Sciences' Collaboration with Charles RiverIntegrated programs that bridge molecules from early discovery to proof of concept (POC) and beyond.
-
WebinarUpcoming Webinar: Strategies for Achieving Regulatory Milestones FasterSave your spot for our next webinar featuring a customer case study from Ensysce Biosciences on April 19, 2023. Dr. Vanessa Zann, Senior Drug Development Consultant, will be joined by Lynn Kirkpatrick, CEO of Ensysce Biosciences for this special presentation.
Get in touch
Humanity can’t afford to wait, so neither can we.
Let’s talk.